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Eosinophilic esophagitis (EoE) is a chronic disease characterized clinically by symptoms 
of esophageal dysfunction and histologically by eosinophil-predominant inflammation. 
EoE is frequently associated with concomitant atopic diseases and immunoglobulin E 
(IgE) sensitization to food allergens in children as well as to aeroallergens and cross-
reactive plant allergen components in adults. Patients with EoE respond well to elemental 
and empirical food elimination diets. Recent research has, however, indicated that the 
pathogenesis of EoE is distinct from IgE-mediated food allergy. In this review, we discuss 
the individual roles of epithelial barrier defects, dysregulated innate and adaptive immune 
responses, and of microbiota in the pathogenesis of EoE. Although food has been 
recognized as a trigger factor of EoE, the mechanism by which it initiates or facilitates 
eosinophilic inflammation appears to be largely independent of IgE and needs to be 
further investigated. Understanding the pathogenic role of food in EoE is a prerequisite 
for the development of specific diagnostic tools and targeted therapeutic procedures.  
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Current definition of EoE 
As a consequence of intense research in the field of esophageal eosinophilia, our 
understanding of eosinophilic esophagitis (EoE) has developed from strict clinic-
pathologic criteria leading towards a conceptual definition which includes pathogenic 
aspects (1-3). According to current recommendations, EoE represents a chronic, 
immune/antigen-mediated esophageal disease characterized clinically by symptoms of 
esophageal dysfunction and histologically by eosinophil-predominant inflammation (2). 
EoE has been recognized as having a spectrum of clinical signs and symptoms, 
endoscopic findings as well as pathologic features. However, the term “immune/antigen-
mediated” does not address the question where EoE should be positioned in the wide 
range between autoimmune and allergic diseases. In addition, there are likely subgroups 
of patients who do not meet this strict definition; for example, some have less than 15 
eosinophils per high power field (hpf), but otherwise fulfill the criteria of EoE (2).  
The two most common causes of eosinophilia in the esophagus, normally devoid 
of eosinophils in healthy humans, are gastroesophageal reflux (GERD) and EoE (2). 
However, yet another form of esophageal eosinophilia has recently emerged having 
clinical manifestations and histological features indistinguishable from EoE, but distinct 
from GERD, apart from the fact that it is responsive to high-dose of PPI whereas EoE is 
histologically refractory to PPI. Hence, it is called PPI-responsive esophageal eosinophilia 
(PPI-REE) (4,5). Patients with PPI-REE frequently exhibit environmental and/or food 
allergen sensitizations like patients with EoE, whereas the atopy rate in patients with 
GERD is similar to that of the general population. Moreover, the inflammatory markers of 
PPI-REE are more similar to those of EoE than of GERD: positive for factors involved in 
eosinophil chemotaxis (eotaxin 3, CCL26), barrier integrity (desmoglein 1, DSG1), tissue 
remodeling (periostin, POSTN), and mast cell specific activity (carboxypeptidase A, 
CPA3) (4). The molecular signature typical of PPI-REE and EoE could be reversed by 
PPI therapy only in PPI-REE (4), suggesting the molecular signature is either a sign of 
disease or marker of eosinophilic inflammation. Mechanisms proposed to explain the PPI 
response include an acid-independent, anti-inflammatory action of PPIs on the one hand, 
or a PPI-induced restoration of esophageal barrier function on the other (6). In summary, 
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it is possible that PPI-REE and EoE are the consequence of the same underlying 
immunologic mechanism, but additional research is required to confirm this concept.  
Already early reports on EoE mentioned concomitant allergic diseases and 
elevated total serum immunoglobulin E (IgE) levels in about 70% of the patients (7,8). 
After receiving elemental formulas, children with esophageal eosinophilia not responding 
to pharmacological and/or surgical anti-reflux therapy, showed marked improvements (9). 
This observation suggested that EoE could represent an allergic disease in which food 
proteins play an important role. However, further research revealed that EoE seems not 
to be simply an IgE-mediated food allergy. What, then, are the underlying causes of EoE 
and what role might food and/or other antigens play in the pathogenesis? In this review 
initiated by the EAACI Eosinophilic Esophagitis Interest Group, we will discuss recently 
published work on EoE in the context of an immune/antigen-mediated disease. 
 
EoE-associated IgE-sensitization to food and aeroallergens 
EoE is associated with elevated total IgE levels as well as IgE-sensitization to food and 
aeroallergens (10). In a pediatric EoE cohort, sensitizations to food and environmental 
allergens have been observed in 75% and 79%, respectively (11). Skin prick testing in 
children with EoE revealed increasing reactivity with inhalant allergen with age, while the 
reactivity to foods decreased (12). Children with EoE were mainly sensitized to milk, eggs, 
soy, wheat/rye, beef and peanuts (13). In adult EoE patients, specific IgEs to food and 
inhalant allergen components have been detected in 91% (14). These patients were 
mainly sensitized to pollens, in particular cross-reactive plant allergen components such 
as profilins and pathogenesis-related (PR)10 proteins (14). Noteworthy is the observation 
of local immunoglobulin class switching and production of IgE in the esophageal mucosa 
of pediatric EoE patients (15). Considering all these findings, EoE was initially suspected 
of being an IgE-mediated allergy to food and cross-reactive plant allergens.  
On the other hand, clinical trials of targeted food elimination diets, as well as of IgE 
blocking, failed to show an IgE-mediated mechanism. Measuring specific IgE levels 
and/or skin prick testing were not sufficient to clearly identify causative food allergens 
(13,14,16,17). Moreover, elimination diets based solely on IgE-sensitization to food 
allergens as determined by skin prick tests (SPT) and/or specific IgE determinations could 
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not improve EoE in a significant number of patients (16,18,19). The positive predictive 
values for causative food identified by SPT ranged from 26% to 96%, with an average of 
47% (16). Based on the assumption that IgE plays a key role in pathogenesis, a therapy 
with an anti-IgE antibody for 12 weeks in pediatric and adult EoE patients was initiated in 
a non-placebo controlled study resulting in a remission rate of only 33% despite an 
effective reduction of IgE levels observed in the esophageal tissue (20). In a double-blind 
placebo-controlled study anti-IgE treatment was not better than placebo in inducing EoE 
remission (21). Taken together, recent clinical and research data lead us to conclude that 
EoE, while often associated with IgE sensitization, is not simply an IgE-mediated food 
allergy. 
 
EoE exhibits features of a Th2 predominant inflammation 
The inflammation of EoE is predominantly eosinophilic, but is also characterized by 
increased numbers of T cells and mast cells infiltrating the esophageal mucosa, as well 
as high expression levels of IL-5 and TNF- (Figure 1) (22). Transcriptome analysis of 
EoE tissue showed a distinct Th2 pattern with significantly elevated mRNA levels of 
eotaxin-3, IL-5, IL-5 receptor -chain and IL-13 (23,24). In experimental models, both 
eotaxin and IL-5 were essential for eosinophil recruitment, accumulation and activation in 
the esophagus as well as for epithelial hyperplasia and remodeling (25-28). Moreover, IL-
13 can induce eotaxin-3 production by esophageal epithelial cells (29). In addition to the 
Th2 cytokines, EoE patients show elevated blood levels of IL-1, IL-6 and IL-8, but lower 
levels of IL-12, IL-17 and CD40L as compared with healthy controls, while the gene 
expression of receptors for IL-1, IL-9 and IL-17 is also upregulated in EoE lesions (23,24).  
Treatment with corticosteroids resulted in a reduced expression of eotaxin-3, IL-5 
and IL-13 and was followed by a decrease of eosinophil numbers in the esophagus of 
EoE patients (29). Although reducing eosinophil inflammation in the esophagus, blocking 
IL-5 or IL-13 with therapeutic antibodies has yet to be proven to be clinically useful, 
although trends have been seen in preliminary studies (30,31). In summary, Th2 immune 
responses are a striking feature and most likely contribute to the pathogenesis of EoE, 
but are not the sole players as pro-inflammatory cytokines are also expressed that may 




Lessons learnt from hypersensitivity reactions of the skin 
EoE shares many similarities with dermatoses that are due to T cell responses of the skin 
independent of IgE. Therefore, it appears logical to consider antigen-triggered T cell-
mediated mechanisms for the pathogenesis of EoE (Figure 1). 
 
T cell responses in allergic contact dermatitis 
In allergic contact dermatitis (ACD), chemical allergens penetrate into the skin where they 
form complexes or bind covalently to proteins of immune and structural cells in the skin 
and, thus, may induce innate immune responses as well as generate T cell epitopes (32). 
Contact allergens, e.g. nickel, are recognized by pattern recognition receptors (PRR) 
resulting in the production of pro-inflammatory cytokines such as IL-1 and IL-18. This 
irritant effect of contact allergens is essential for the subsequent activation of the adaptive 
immune system leading to a Tc1/Th1 and Tc17/Th17 effector/memory T cell response 
(33). Contact hypersensitivity is dependent on T cell-mediated cytotoxicity via FAS/FASL 
and perforin pathways (34). In ACD, Th1/Th17 cells may amplify the cytotoxic cascade 
as they increase T cell–keratinocyte adhesiveness and promote ICAM-1–dependent non-
antigen-specific keratinocyte killing by T lymphocytes (35). However, there is little 
evidence for an IL-17-mediated process in EoE (36).  
 
T cells in drug hypersensitivity 
While immediate allergic drug hypersensitivity reactions (DHR) are mediated by specific 
IgE bound to mast cells and basophils, delayed (non-immediate) allergic DHR are T cell-
mediated. Analogous to haptens, drugs are presented either covalently bound to peptides 
in the binding grove of MHC molecules on antigen-presenting cells or complexed to amino 
acids in MHC molecules and TCR (37). Recently, a concept for the pharmacological 
interaction of drugs with immune receptor (p-i concept) has been proposed, suggesting a 
non-covalent binding enabling a direct interaction with immunological receptors such as 
MHC and TCR (38,39). Thus, the antigen might bind either to the MHC complex, thereby 
modifying the structure that is recognized by the TCR leading to a specific T cell activation 
or directly to a specific TCR requiring additional MHC interaction for full T cell activation 
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(38). In cutaneous reactions, drug-specific cytotoxic T cells have been demonstrated that 
can contribute to tissue damage via perforin/granzyme B or FAS/FASL mechanisms 
(40,41). In DRESS, an oligoclonal expansion of activated CD8+ T cells directed against 
viral antigens derived from Herpes viruses, whose replication is enhanced by the culprit 
drug, has been observed in the skin and visceral organs (42).  
 
Food-specific T cell responses in the skin  
Over 80% of patients with atopic dermatitis (AD) have increased IgEs to foods and 
inhalant allergens in the peripheral blood (43). However, the positive predictive value of 
IgE specific to food allergens is low (44). Interestingly, in 45% of patients reacting upon 
food allergen challenge, eczematous reactions with or without prior immediate reactions 
have been observed, suggesting the occurrence of late, most likely T cell-mediated 
reactions against foods (44). Indeed, in patients with food-triggered AD exacerbations, 
relevant food allergen specific T cells have been detected in the peripheral blood as well 
as the skin (45,46). Moreover, positive atopy patch test (APT) reactions to inhalant and 
food allergens can be detected in the absence of corresponding IgE-responses (47). 
Although widely used, the APT has limited value in the diagnosis of food allergy in EoE 
(16) perhaps owing to the fact that here the skin and not the esophagus is tested. Upon 
food allergen, but not nonspecific stimulation, peripheral blood mononuclear cells from 
EoE patients with or without allergen-specific IgE produce significant amounts of IL-5 (48).  
In peanut-allergic children, skin- and gut-homing T cells expressing Th2 and Th9 genes 
as well as IL-9 and IL-5 production by distinct T helper cell populations have been 
reported (49).   
To date, the presence of food allergen-specific T cells in EoE has not been 
demonstrated. Furthermore, it remains uncertain when and where the sensitization to 
food allergens occurs. In adult EoE patients, airway allergy precedes EoE (50). Recent 
data suggest that an epicutaneous sensitization with ovalbumin may result in an antigen-
induced gastrointestinal food allergy via the TSLP-basophil axis or in an IL-17-mediated 
response depending on the animal model (51,52). Furthermore, filaggrin mutations as 
risk factors for eczema, the atopic march and peanut allergy have been reported, 
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indicating that an impaired epithelial barrier function may predispose to allergen 
sensitization and atopy (53,54).  
 
Epithelial barrier and innate immune responses in EoE 
There is increasing evidence that EoE is associated with a dysfunction at the epithelial 
barrier followed by an eosinophilic inflammation similar to AD which is concomitant in over 
half of EoE patients (Figure 1). In esophageal epithelial cells, the expression of epidermal 
differentiation complex (EDC) genes, e.g. filaggrin, SPRR3 and keratins, is 
downregulated in response to IL-13 and in active EoE, where it could be only partially 
normalized upon therapy (55,56). Desmoglein (DSG)-1, an intercellular adhesion 
molecule responsible for epithelial integrity and barrier function was one of the most 
strongly downregulated genes in EoE (29). A downregulation of DSG-1 gene, e.g. by IL-
13, was shown to result in the separation of epithelial cells (spongiosis) followed by 
impaired barrier function as well as by periostin induction further potentiating inflammation 
(57). Ultrastructural analysis revealed a significantly decreased number of desmosomes 
per cell in EoE biopsies as compared to healthy controls, which was reversible after 
treatment (58). Furthermore, the expression of filaggrin and the tight junction proteins 
zonula occludens (ZO)-3 and claudin-1 is decreased in EoE, correlating with spongiosis 
(59). Consistent with this finding, mutations in filaggrin are over-represented in EoE 
patients (55) and homozygous mutations of DSG1 cause a severe atopy syndrome which 
includes EoE (60). 
In stratified epithelia, the activity of proteases is tightly regulated by protease 
inhibitors. The loss of inhibition results in cleavage of desmosomal proteins and loss of 
barrier integrity, facilitating the penetration of allergens and microbes as well as the 
subsequent generation of danger signals and protease activated receptor (PAR)-2 
activation (61). In active EoE, a significantly decreased expression of the protease 
inhibitor LEKTI has been observed (36).   
TSLP that is produced by epithelial cells in response to PAR-2, toll-like receptor 
(TLR) stimulation or mechanical injury, strongly induces Th2 immune responses by 
stimulating dendritic cells, T cells, eosinophils, mast cells and basophils (62). Upon 
stimulation with TSLP, eosinophils that bear the TSLP receptor on their surface generate 
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extracellular DNA traps associated with granule proteins that are able to kill bacteria (63). 
Interestingly, the expression of TSLP is increased in EoE and correlates with the number 
of eosinophils generating eosinophil extracellular traps (36). Genetic variants of TSLP 
and its receptor have been associated with an increased susceptibility to EoE overall, and 
in males, respectively (64,65). Furthermore, the gene of esophageal selective calpain 
(CAPN) 14, a member of the calpain protease family involved in the cleavage of 
inflammatory mediators such as IL-33, was upregulated in active EoE, while the calpain 
inhibitor CAST was downregulated (66). In line with these findings, genetic variants in the 
CAPN 14 gene locus are linked with EoE susceptibility (67) and increased expression of 
innate cytokines including IL-33 by epithelial cells has been detected in EoE (36). 
Immense efforts have been undertaken to identify the role of the microbiota in the 
immune system, in particular in association with immune-mediated diseases. Microbiota 
research aims at elucidating their role in initiating and perpetuating inflammation and, 
conversely, the effect of diseases and treatment procedures on the microbiota. Compared 
to healthy controls, the bacterial load of the esophagus is increased in EoE patients 
regardless of treatment and disease activity, with a relative abundance of gram-negative 
bacteria in active EoE (68,69).  Recently, IgE-sensitization to Candida albicans has been 
reported in pediatric and adult EoE patients (14,70). Whether an esophageal colonization 
with Candida albicans and later sensitization is owing to EoE inflammation or 
corticosteroid therapy remains to be investigated. Furthermore, any potential role of IgE 
specific for Candida albicans in the pathogenesis of EoE is uncertain.  
Taken together, recent research suggests that impaired epithelial barrier function 
plays a major role in initiating and perpetuating EoE inflammation as it facilitates the 
penetration of allergens and microbes and generates danger signals leading to an 
activation of epithelial cells as well as innate and adaptive immune cells with subsequent 
chemokine and cytokine production resulting in Th2 immune responses. There is 
evidence of a dysbiosis of microbiota in EoE, however, the consequences in terms of 
microbial-triggered eosinophilic inflammation and the particular role of diet on the 
microbiome in the esophagus remain to be investigated. 
 
Similarities and differences between EoE and IBD 
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With inflammatory bowel diseases (IBD), such as Crohn’s disease (CD) and ulcerative 
colitis (UC), the pathogenesis is determined by genetic factors, environmental and 
microbial factors together with an epithelial barrier dysfunction and subsequent innate 
and adaptive immune responses (71). The susceptibility to IBD is determined by genetic 
variants related to innate immunity, autophagy and phagocytosis in CD and to barrier 
function in UC (72). Due to an increased intestinal epithelial permeability, food antigens 
and microbes may activate pattern recognition receptors on epithelial cells resulting in a 
release of pro-inflammatory cytokines such as TNF-, IL-1, IL-18 and IL-33 (Figure 1) 
(71). In contrast to EoE, predominantly Th1 cells and the IL-23/Th17 axis are activated in 
IBD (71). It has been hypothesized that due to a dysregulated innate intestinal immunity 
and barrier function, affecting both the diversity and composition of the microbiota, the 
immune response is initiated to eliminate invading antigens (e.g. microbes, food) and to 
restore epithelial barrier integrity, but may later turn into a chronic inflammation leading 
to the clinical manifestations of IBD (71,73).  
Thus, the principal pathomechanisms of IBD seem congruent with those of EoE, 
although it is currently not clear which tissue-specific characteristics, including immune 
responses, environmental factors such as microbiota and food, as well as genetic 
predispositions favor a chronic Th1/Th17 inflammation as in IBD or a Th2 predominant 
inflammation as in EoE with corresponding clinical phenotypes. While both diseases have 
common mechanisms, the upstream events are likely to be different as EoE is associated 
with unique genetic susceptibility (TSLP and CAPN14) and atopy; whereas IBD is more 
related to innate immunity to microbial flora. 
 
EoE is distinct from IgE-mediated food allergies 
If one were to consider EoE as a kind of food allergy, how would its symptoms agree with 
the current concept of gastrointestinal (GI) allergies? A food allergy is defined as an 
abnormal immunologic response to a food substance occurring in a susceptible host and 
causing some type of GI inflammation. The vast majority of food allergies affecting the GI 
tract are characterized by a Th2 inflammation with predominant Th2 cytokine expression 
(that is IL-4, IL-13, and IL-5). Th2 inflammation can cause B cells to produce IgE 
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antibodies specific to certain foods or can lead to a chronic cellular inflammation 
frequently characterized by the presence of Th2 cell and eosinophils  (74).  
According to the immunological mechanism elicited, food allergies can be 
classified into: (a) IgE-mediated, which are immediate, short-lived reactions mediated by 
antibodies belonging to the IgE class, (b) cell-mediated, which usually have a 
delayed/chronic course, typically involving the GI tract and the cell component of the 
immune system responsible for inflammation, or (c) mixed, IgE- and cell-mediated (75). 
IgE-mediated reactions to foods are acute and highly reproducible. They are initiated by 
the cross linking of two or more allergen-specific IgE antibodies bound to their high-affinity 
receptor (FcεRI) expressed on mast cells and basophils as a result of a specific food 
allergen engagement. Such cross-linking determines the release of preformed mediators, 
in particular, histamine, that cause vasodilatation, angioedema, smooth muscle 
constriction, and increased mucus production (76).  
Examples of typical IgE-mediated allergic reactions affecting the GI tract are the 
oral allergy syndrome (OAS) and the more severe GI food allergy, also known as 
“gastrointestinal anaphylaxis”. When comparing IgE-mediated OAS and GI food allergies 
with EoE, the following differences become evident: EoE symptoms might be instant, but 
they are not transient, EoE inflammation is chronic, anaphylaxis is not a feature of EoE, 
and pollen-associated food allergens are not a typical trigger of EoE. It should be noted, 
however, that EoE patients can concurrently suffer from OAS and/or a GI food allergy. 
Food protein-induced enterocolitis (FPIES), an increasingly recognized form of 
non-IgE mediated food hypersensitivity,  is characterized by a delayed onset of vomiting 
with or without diarrhea, typically occurring in infants and toddlers from 2 to 6 h post-
ingestion of the trigger food (77,78). FPIES is usually a transient disease which starts at 
4 to 9 months of life or when solid foods are first introduced, and resolves by age 2 to 5 
years (77). The foods most commonly involved in FPIES are milk, soy, rice, oats and 
eggs. IgEs specific to the trigger foods are usually not detectable (77,79). Although FPIES 
and EoE seem to share some clinical (symptoms, age of onset) and pathogenic 
(causative food triggers, increased TNF-, epithelial barrier defects) features (80), other 
characteristics such as disease course, endoscopic and histologic findings discriminate 




Experience with omalizumab: Its lack of clinical efficacy in EoE 
Omalizumab is an anti-IgE humanized monoclonal antibody that binds to the fragment 
crystallizable (Fc) region of the IgE molecule and thus prevents its binding to the high-
affinity IgE receptor (Fc epsilon RI, FcεRI). In the only published prospective, randomized, 
double-blind, placebo-controlled study in 30 adult EoE patients (16 treated with 
omalizumab and 14 with placebo) omalizumab was given every 2-4 weeks for 16 weeks, 
based on weight and serum level of IgE. Before starting the treatment and at the end of 
the trial (16 weeks of treatment) symptoms evaluation, EGD and histological assessment 
of the eosinophil density (peak eos/hpf) in esophageal biopsies were performed. Patients 
treated with omalizumab had neither a significant improvement in symptoms nor a 
decrease of the eosinophil infiltration of the esophageal mucosa compared with placebo 
(21). This study confirmed anecdotal data from clinical cases reported in which 
omalizumab had been considered to improve IgE-mediated symptoms of food allergy, but 
not of EoE (81). Overall these data support the notion that EoE is not IgE-mediated. 
Clayton et al. speculated that IgG4 antibodies specific for a food allergen are blocking IgE 
responses (21). Indeed, in allergic diseases, an IgG4 response follows an IgE-mediated 
response and does block IgE-mediated mast cell activation (21). In EoE, extracellular 
granular deposits of IgG4 and abundant IgG4-containing plasma cells in the tissue, as 
well as increased serum levels of IgG4 reactive with specific foods have been observed, 
suggesting that in adults, EoE might be an IgG4- and IgE-associated disease and 
perhaps the balance between the two antibodies could be a key determinant (21). 
However, B cell-deficient mice also develop typical EoE, suggesting that antibodies may 
simply be non-pathogenic (82). Moreover, the anti-food IgG4 levels did not correlate with 
the age and duration of disease symptoms (21). Further studies will be necessary to really 
understand the pathogenic role of IgG4 in EoE.   
 
EoE is characterized by a non-IgE-mediated food hypersensitivity 
Since the first description of a series of clinical cases of EoE, food allergies have 
appeared to play a major role in causing a severe esophageal eosinophilia that resolved 
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on elemental diet, but not on aggressive GERD treatment, including Nissen fundoplication  
(6). In view of this, food allergens have been identified as triggers of EoE in most children 
and adults (6,16,82,83). 
 Thus, food as a trigger of EoE fulfills Koch’s postulates since addition or 
subtraction of foods can cause disease or eliminate disease in EoE in nearly all patients. 
The most effective treatment in patients with EoE is an elemental diet that induces 
histological and clinical resolution in over 95% of pediatric and adult patients (83-86). 
Noteworthy is that IBD may also resolve upon elemental diet (87) with a mechanism that 
involves both bowel rest and a change in microbiome. So far, the explanation for 
remission of EoE on an elemental diet has always been linked to the avoidance of food 
allergens, rather than bowel rest/change in microbiome, but this possibility needs to be 
investigated further. This presumption was supported by the fact that elimination diets 
based on removal of the six most common food allergens (SFED-six food elimination diet) 
(82) or of the foods to which patients were sensitized (targeted elimination diets) have 
been shown to induce and maintain EoE remission in 72% and 45% of EoE patients, 
respectively (16,88). According to biopsy confirmation, the most common food proteins 
causing EoE are milk, followed by wheat, eggs, beef, soy and legumes, and chicken 
(16,83,89,90). Interestingly, peanuts, tree nuts, fish and shellfish are rare as causes for 
EoE despite being common causes of IgE-mediated reactions in adults.   
The evidence that EoE is generally non-IgE-mediated is based on both clinical and 
research findings: 
(1) Despite the fact that the majority of patients with EoE have specific IgEs to food 
allergens and/or aeroallergens, the detection of specific IgEs for food allergens, either by 
SPT or specific sera IgE (sIgE), has not proven successful for the identification of 
causative foods in EoE (84,85). Indeed, removal of SPT or sIgE positive foods is not 
superior to SFED (2,16,17,83,91). Moreover, it has been reported that the introduction of 
skin test negative foods into the diet sometimes induces clinical disease (6,16). 
(2) Clinical trials and case series have shown that therapy with omalizumab is not effective 
in inducing remission of EoE (21,81). 
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(3) Oral immunotherapy, which has been used successfully in IgE-mediated food allergy, 
is associated with an increased risk of developing EoE (e.g. in 2 to 10% of treated 
patients) (92-94).  
(4) Children who outgrow IgE-mediated food allergy and therefore are able to reintroduce 
these foods in their diet, can later develop EoE to the same food (95). 
(5) In experimental models in which food allergens are able to induce an EoE-like disease, 
mice with depleted IgE and devoid of mast cells still could develop esophageal 
inflammation and consequent food impaction similar to the wild-type mice (96,97).  
 
Confirmation of EoE diagnosis and the practical search for offending foods  
EoE is a clinico-pathological diagnosis. However, EoE and GERD have a substantial 
overlap of clinical and of histological features. For instance, the presence of heartburn 
and marked esophageal eosinophilia might be fairly common in both entities (2). In order 
to solve this diagnostic conundrum, updated consensus recommendations for diagnosis 
and management of EoE advocate performing a PPI trial in patients having symptoms 
suggestive of EoE and esophageal eosinophilia (2). Accordingly, a diagnosis of GERD 
was recommended for those patients responding to PPI therapy, whereas patients whose 
symptoms and inflammation persist were regarded as having EoE (2). Unfortunately, this 
diagnostic PPI trial did not fulfil the expectation of differentiating EoE from GERD, but 
unexpectedly uncovered a third category of patients, called PPI-REE, presenting with 
symptoms of EoE, but responding to PPI (5). With the exception of the responsiveness 
to PPI, PPI-REE, and EoE have common clinical, endoscopic, histological and molecular 
features. 
EoE is a chronic and progressive disease. If left untreated complications, such as 
food impaction, esophageal stricture, narrow-caliber esophagus, and esophageal 
perforation are common (98,99). Therefore, once the diagnosis is confirmed, it is 
important to treat the eosinophilic inflammation not only to control the presenting 
symptoms, but also to preserve the morphological and functional integrity of the 
esophagus (2,10,87,99). Beside medications, diets avoiding culprit foods are an important 
therapeutic option (100). Of note, before an elimination diet can be established, it is 
necessary to identify the triggering foods, ideally with the help of a dietitian specialized in 
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dealing with this disease. Currently culprit foods are identified by demonstrating 
histological and clinical remission of EoE after the establishment of an elimination diet. In 
practice, after avoidance and after re-introduction of any food category, the effect must 
be controlled endoscopically and histologically (82,83). Serial endoscopies are therefore 
required to figure out an individual elimination diet. This approach is time consuming, 
inconvenient for patients, expensive, and affects the quality of life (101). Therefore, there 
is a need to develop non-invasive methods for the identification of the offending foods. 
The determination of food-specific IgG4 in the serum is a method currently under 
evaluation. Further phenotyping patients based on their esophageal gene expression, 
using a 94 gene transcript profile, is promising to be helpful (102). 
 
Conclusions 
There is strong evidence that foods, most likely food-proteins, are triggers of EoE, since 
elimination of culprit food categories as well as protein-free elemental diets result in an 
improvement of histological and endoscopic signs as well as of symptoms. Furthermore, 
the observation that the eosinophilic inflammation and the Th2 inflammation pattern 
reappear rapidly after re-introduction of the culprit foods are strong arguments that EoE 
is likely a food-driven disorder with features of food allergy. However, the spectrum of 
clinical presentations of EoE, the results of IgE-based diagnostic procedures, as well as 
the lack of efficacy of anti-IgE treatment suggests that EoE cannot be regarded as an 
IgE-mediated food allergy.  
The mechanism by which food elicits EoE is not yet understood. It seems likely 
that a cellular mechanism similar to contact allergy of the skin or drug hypersensitivity 
plays a role. IgG4 formed against foods has been suspected of playing a role in EoE, 
perhaps as a blocking antibody analogous to AD and IBD, an impairment of the epithelial 
barrier, alterations of the microbiota and subsequent chronic inflammation might be the 
underlying pathogenic factors for EoE. Given this scenario, food might interfere either as 
an irritant, modulator of the microbiota or as an antigen/allergen to initiate and perpetuate 
inflammation (Figure 1). The identification of offending foods by empirical elimination diets 
and controlled re-introduction of foods is inconvenient for patients, time-consuming, and 
in the clinical routine hardly applicable. Nevertheless, this procedure is currently the only 
17 
 
reliable method to identify food triggers in EoE patients. Elucidating the exact mechanism 
of how foods affect EoE would allow the development of novel diagnostic tests. For 
instance, the determination of food-specific markers including T cell responses to specific 
foods could possibly overcome the limitations of SPT, APT, and empirical diets. As in IBD 
and atopic diseases, EoE should be considered as a complex disease with a disordered 
interplay between the epithelial barrier, innate and adaptive immune responses together 
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Figure 1  Food as a trigger in the pathogenesis of EoE. (A) In addition to the presence 
of a genetic predisposition or reflux disease, a food allergy would further disrupt the 
epithelial barrier and affect the microbiota. (B) Food allergens could then penetrate also 
in the skin, bind to pathogen-related receptors and activate epithelial cells to produce pro-
inflammatory cytokines responsible for the recruitment and activation of inflammatory 
cells including eosinophils. (C) Antigen-presenting cells capturing food antigens, would 
migrate to the regional lymph nodes where they stimulate food-specific T cells. Food 
proteins may induce T cell responses either as a consequence of antigen presentation by 
dendritic cells (D) or directly (E) with subsequent eosinophil activation. By releasing toxic 
granule proteins and cytokines, eosinophils defend against invading pathogens, but 
cause tissue damage, stimulating fibrosis and perpetuating inflammation. The 
pathomechanisms of EoE overlapping with other diseases are indicated. 
